COMMUNIQUÉS West-GlobeNewswire

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
30/07/2026
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company’s large, randomized Phase II study, OVATION 2 Strong enrollment [...]
Diakonos Oncology Announces First Patients Dosed in Phase 1/2 DOC-RM Study of DOC1021 in Refractory Melanoma
30/07/2026
First patients dosed at City of Hope and the University of Alabama at Birmingham DOC-RM recently featured as a Trial-in-Progress presentation at the 2026 ASCO Annual Meeting FDA Fast Track designation granted for [...]
Communiqué de presse : Rapport financier semestriel 2026 de Sanofi
30/07/2026
Rapport financier semestriel 2026 de Sanofi Paris, le 30 juillet 2026 . Sanofi annonce aujourd’hui avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers (AMF) son rapport financier [...]
Leo International Precision Health AG: Mr Leo Wang, Acquisition
30/07/2026
Leo International Precision Health AG: Mr Leo Wang, Acquisition Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 30. Jul [...]
Applied Biologics Announces Successful GMP Manufacturing of Initial Clinical Lots of BIOxHEAL™
30/07/2026
Manufacturing milestone supports planned clinical development of the Company’s lead investigational biologic for chronic wounds SCOTTSDALE, Ariz., July 30, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical [...]
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
30/07/2026
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. [...]
Press Release: Sanofi’s half-year financial report for 2026
30/07/2026
Sanofi’s half-year financial report for 2026 Paris, July 30, 2026 . Sanofi announces that its half-year financial report for the period ending June 30, 2026, is now available online and has been filed with the French [...]
MMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patients
30/07/2026
FDA-approved supplement advances early feasibility study (EFS) toward full enrollment JACKSONVILLE, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- MMI (Medical Microinstruments, Inc.), a robotics company dedicated to [...]
CorVascular Launches ASUS Handheld Ultrasound Portfolio for Vascular Specialists at SVU 2026
30/07/2026
Exclusive U.S. Distributor to Showcase Live Demos of the FDA-Cleared Wireless LU800 Featuring Up to 2.5 Hours of Continuous Operation MINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- CorVascular today announced the [...]
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
30/07/2026
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
30/07/2026
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a [...]
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
30/07/2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR- [...]
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
30/07/2026
As of July 29, 2026, trading volume on the Rain protocol reached $860MM 1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. ( [...]
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
30/07/2026
ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second [...]
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in [...]
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30/07/2026
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not [...]
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
30/07/2026
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of [...]
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a [...]
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
30/07/2026
Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or [...]

Pages